Studies brain tissue removed from people with drug-resistant epilepsy
Examines inhibitory brain signaling in brain tissue removed from people with epilepsy.
Plain-language title generated from the registry record
Registry title: Functional Study of Inhibitory Neurotransmission in the Human Epileptic Brain.
Key facts
- Where
- Pozzilli, ItalySee the site
Where in Italy
- IRCCS INM NeuromedPozzilli, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Neuromed IRCCS
- Trial code
- NCT05459090
- Record updated
- 2 August 2022
- Original description
Epilepsy is a neurological condition that afflicts 1% of the world population. 30% of patients become drug-resistant to classic antiepileptic treatment and only a small percentage, 5%, can undergo a neurosurgical resection of epileptic focus and recover almost completely from symptoms. To date, an imbalance between inhibitory and excitatory neurotransmission has been well accepted as the main root cause of epilepsy. A better understanding of the molecular mechanisms of this can lead to developing new therapeutic strategies. The investigators of the project want to describe the functional alteration of GABA- A receptor, the main actor of inhibitory neurotransmission in the central nervous system and characterize its subunit composition in the epileptic foci of patients with temporal lobe epilepsy. The authors, also, want to modulate, by means of selective neuroactive molecules, the function of this receptor to increase the inhibitory tone in the epileptic brain.Read full original descriptionShow less
Functional Study of Inhibitory and Excitatory Neurotransmission in the Nervous Tissue Resected From Human Brain: Understanding New Molecular Mechanisms and Discovering New Therapeutic Targets to Cure Drug-resistant Epilepsy.
Epilepsy is a neurological condition that afflicts 1% of the world population. 30% of patients become drug-resistant to classic antiepileptic treatment and only a small percentage, 5%, can undergo a neurosurgical resection of epileptic focus and recover almost completely from symptoms. To date, an imbalance between inhibitory and excitatory neurotransmission has been well accepted as the main root cause of epilepsy. A better understanding of the molecular mechanisms of this can lead to developing new therapeutic strategies. The investigators of the project want to describe the functional alteration of GABA- A receptor, the main actor of inhibitory neurotransmission in the central nervous system and characterize its subunit composition in the epileptic foci of patients with temporal lobe epilepsy. The authors, also, want to modulate, by means of selective neuroactive molecules, the function of this receptor to increase the inhibitory tone in the epileptic brain.
Inclusion: Patients with drug-resistant temporal lobe epilepsy.
Exclusion: Patients suffering from Temporal lobe epilepsy caused by stroke, ischemia, cavernous angiomas, or meningiomas growth.